

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Ruddy *et al.*
MAIL DATE CANCELLED

Application No.: 08/852,495

Filed: May 7, 1997

For: POLYMORPHISMS IN THE
REGION OF THE HUMAN
HEMOCHROMATOSIS GENE

Group Art Unit: 1644

Examiner: Vander Vegt, F.

Attorney Docket No.: 8907-057-999

RECEIVED

FEB 12 2001

ED

TECH CENTER 1600/2900

FEE TRANSMITTAL SHEET

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The fee required to be filed with the accompanying amendment of even date herewith concerning the above-identified application has been estimated to be \$734.

The claim amendment fee has been estimated as shown below:

(Col. 1)	(Col. 2)	(Col. 3)	SMALL ENTITY	OTHER THAN A SMALL ENTITY
CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NO PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDIT. FEE
TOTAL 51	MINUS 28	= 23	× 9 \$	× 18 \$ 414.00
INDEP. 10	MINUS 6	= 4	× 40 \$	× 80 \$ 320.00
<input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEP. CLAIM			135 \$	270 \$
			TOTAL \$	OR TOTAL \$ 734.00

Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150 (order no. 8907-057-999). A copy of this sheet is enclosed.

Respectfully submitted,

Date January 31, 2001

Ann M. Caviani Pease

42,067

(Reg. No.)

for Brian M. Poissant (Reg. No. 28,462)
 PENNIE & EDMONDS LLP
 1155 Avenue of the Americas
 New York, New York 10036-2711
 (212) 790-9090

Enclosure



Express Mail No.: EL 451 596 129 US

LS
JF
2/15/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Ruddy *et al.*

RECEIVED

Serial No.: 08/852,495

Group Art Unit: 1644

FEB 12 2001

Filed: May 7, 1997

Examiner: Vander Vegt, F.

TECH CENTER 1600/2900

For: POLYMORPHISMS IN THE REGION OF
THE HUMAN HEMOCHROMATOSIS
GENE

Attorney Docket No.:
8907-057-999

AMENDMENT UNDER 37 C.F.R. § 1.111

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants have considered the Office Action dated July 31, 2000, and request reconsideration of the claims in view of the following amendments and remarks. Applicants submit concurrently herewith (1) an Exhibit A, which sets forth the claims as pending after entry of this Amendment; (2) a Terminal Disclaimer; (3) an Amendment Fee Transmittal Sheet; and (4) a Petition for Extension of Time Under 37 CFR § 1.136(a) extending the period for response by three months, up to and including January 31, 2001, accompanied by the appropriate fee.

AMENDMENTS

IN THE SPECIFICATION:

Please amend the specification as follows:

02/06/2001 YPOLITE1 00000092 161150 08852495

01 FC:102 320.00 CH
02 FC:103 414.00 CH